NBLST1
MCID: NRB001
MIFTS: 73

Neuroblastoma (NBLST1)

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuroblastoma

MalaCards integrated aliases for Neuroblastoma:

Name: Neuroblastoma 58 12 77 54 26 60 38 30 13 6 44 45 15 41 17 74
Neuroblastoma 1 58 76 30 6
Nb 54 26
Neuroblastoma, Susceptibility to, Type 1 41
Neuroblastoma, Susceptibility to, 1 58
Neuroblastoma, Susceptibility to 58
Central Neuroblastoma 74
Nblst1 76

Characteristics:

Orphanet epidemiological data:

60
neuroblastoma
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Childhood; Age of death: adolescent,late childhood;

OMIM:

58
Inheritance:
autosomal dominant
somatic mutation

Miscellaneous:
genetic heterogeneity
incomplete penetrance
mean age of onset 14-24 months
highly variable clinical phenotype
symptoms vary according to location of tumor
spontaneous tumor regression may occur
usually sporadic, but 1-2% of cases are familial
n-myc oncogene amplification is associated with poor prognosis


HPO:

33
neuroblastoma:
Onset and clinical course incomplete penetrance
Inheritance heterogeneous autosomal dominant inheritance sporadic


Classifications:

Orphanet: 60  
Rare neurological diseases


Summaries for Neuroblastoma

NIH Rare Diseases : 54 Neuroblastoma is a tumor that develops from neuroblasts (immature nerve tissue) in an infant or child, usually before the age of 5. It most often develops in infancy and may be diagnosed in the first month of life. The tumor most often develops in the adrenal gland, but may develop in the neck, chest, or spinal cord. It is considered an aggressive tumor because it often spreads to other parts of the body (metastasizes). In most cases, it has spread by the time it is diagnosed. A neuroblastoma can cause a variety of signs and symptoms, including a lump where the tumor is growing, bone pain, diarrhea, and various neurological symptoms. The cause of most neuroblastomas is not known. Rarely, a neuroblastoma is caused by an inheritedmutation in a gene, such as the ALK gene or PHOX2B gene. Diagnosing a neuroblastoma may rely on a physical examination, blood tests, imaging tests (such as MRI or CT scan) and ultimately, a biopsy. Treatment depends on the size and location of the tumor within the body, as well as the child�??s age. Surgery is often the first step of treatment, and may be followed by chemotherapy, radiation therapy, or a stem cell transplant in more severe cases. In some children the tumor goes away without treatment. While the long-term outlook and chance of survival depends on many factors, the 5-year survival rate ranges from 40-50% in some, to over 95% in others. The child's doctor is in the best position to provide personalized information about the outlook in each case.

MalaCards based summary : Neuroblastoma, also known as neuroblastoma 1, is related to medulloblastoma and glioma, and has symptoms including seizures, tremor and back pain. An important gene associated with Neuroblastoma is ALK (ALK Receptor Tyrosine Kinase), and among its related pathways/superpathways is Transcriptional misregulation in cancer. The drugs Miconazole and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include adrenal gland, bone and bone marrow, and related phenotypes are neoplasm of the nervous system and elevated urinary catecholamines

Disease Ontology : 12 An autonomic nervous system neoplasm that derives from immature nerve cells.

Genetics Home Reference : 26 Neuroblastoma is a type of cancer that most often affects children. Neuroblastoma occurs when immature nerve cells called neuroblasts become abnormal and multiply uncontrollably to form a tumor. Most commonly, the tumor originates in the nerve tissue of the adrenal gland located above each kidney. Other common sites for tumors to form include the nerve tissue in the abdomen, chest, neck, or pelvis. Neuroblastoma can spread (metastasize) to other parts of the body such as the bones, liver, or skin.

OMIM : 58 Neuroblastoma is the most common childhood cancer diagnosed before the age of 1 year, and accounts for 10 to 15% of all cancer deaths in children. Some patients inherit a genetic predisposition to neuroblastoma due to germline mutations, whereas others develop sporadic disease that may result from either germline or somatic mutations. Neuroblastoma tumors are derived from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system (Roberts et al., 1998; Eng, 2008). Histopathologically, neuroblastoma can range in type from the most aggressive form, neuroblastoma, composed entirely of immature neural precursor cells, to ganglioneuroma, composed entirely of mature neural tissue. The most important prognostic factor for patients with neuroblastoma is the extent of the tumor at the time of diagnosis (Roberts et al., 1998). Neuroblastoma can also be part of cancer-prone syndromes, such as paragangliomas (see, e.g., PGL4; 115310). (256700)

MedlinePlus : 44 Neuroblastoma is a cancer that forms in your nerve tissue. It usually begins in the adrenal glands, which sit atop your kidneys. It may also begin in your neck, chest or spinal cord. The cancer often begins in early childhood. Sometimes it begins before a child is born. By the time doctors find the cancer, it has usually spread to other parts of the body. The most common symptoms are A lump in the abdomen, neck or chest Bulging eyes Dark circles around the eyes Bone pain Swollen stomach and trouble breathing in babies Painless, bluish lumps under the skin in babies Inability to move a body part Treatments include surgery, radiation therapy, chemotherapy, biologic therapy, or a combination. Biologic therapy boosts your body's own ability to fight cancer. Sometimes before giving treatment, doctors wait to see whether symptoms get worse. This is called watchful waiting. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 76 Neuroblastoma 1: A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.

Wikipedia : 77 Neuroblastoma (NB) is a type of cancer that forms in certain types of nerve tissue. It most frequently... more...

Related Diseases for Neuroblastoma

Diseases in the Neuroblastoma family:

Neuroblastoma 2 Neuroblastoma 3
Neuroblastoma 4 Neuroblastoma 5
Neuroblastoma 6 Neuroblastoma 7

Diseases related to Neuroblastoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 552)
# Related Disease Score Top Affiliating Genes
1 medulloblastoma 32.9 FGFR1 H19 MIR34A MYCNOS TP53
2 glioma 31.4 FGFR1 H19 HAGLR MIR184 MIR34A TP53
3 rhabdomyosarcoma 31.3 ALK H19 PTPN11 TP53
4 glioblastoma 31.2 ALK FGFR1 H19 MIR34A TP53
5 astrocytoma 31.1 FGFR1 H19 LINC00467 PTPN11 SNHG1
6 melanoma 30.9 CASC15 H19 MIR184 MIR34A TP53
7 lung cancer 30.8 ALK FGFR1 H19 HAGLR MIR34A NME1
8 adenocarcinoma 30.6 ALK FGFR1 H19 TP53
9 ovarian cancer 30.3 H19 HAGLR MIR184 NBAT1 NME1 SNHG16
10 adrenocortical carcinoma, hereditary 30.2 H19 MIR184 TP53
11 osteogenic sarcoma 30.2 H19 SNHG1 TP53
12 thyroid cancer, nonmedullary, 1 29.9 H19 HAGLR MIR34A
13 hepatocellular carcinoma 29.8 CASC15 DBH-AS1 FGFR1 H19 HAGLR MIR34A
14 olfactory neuroblastoma 12.5
15 neuroblastoma 2 12.5
16 neuroblastoma 3 12.5
17 cervical neuroblastoma 12.4
18 cerebral neuroblastoma 12.3
19 adrenal neuroblastoma 12.3
20 nijmegen breakage syndrome 12.2
21 differentiating neuroblastoma 12.2
22 extracranial neuroblastoma 12.2
23 spinal cord neuroblastoma 12.2
24 retroperitoneal neuroblastoma 12.2
25 renal cell carcinoma associated with neuroblastoma 12.1
26 neuroblastoma 4 12.1
27 neuroblastoma 5 12.1
28 neuroblastoma 6 12.1
29 nasal cavity olfactory neuroblastoma 12.1
30 neuroblastoma 7 12.0
31 mediastinum neuroblastoma 12.0
32 nicolaides-baraitser syndrome 11.9
33 retinoblastoma 11.8
34 opsoclonus-myoclonus syndrome 11.5
35 central hypoventilation syndrome, congenital 11.5
36 ganglioneuroblastoma 11.4
37 wilms tumor 1 11.4
38 weaver syndrome 11.3
39 myoclonic encephalopathy of infants 11.3
40 nijmegen breakage syndrome-like disorder 11.3
41 cohen syndrome 11.3
42 adrenal carcinoma 11.3
43 duarte variant galactosemia 11.2
44 askin's tumor 11.0
45 simpson-golabi-behmel syndrome 11.0
46 hirschsprung disease ganglioneuroblastoma 11.0
47 parameningeal embryonal rhabdomyosarcoma 10.7 ALK TP53
48 hematologic cancer 10.7 ALK FGFR1 PTPN11 TP53
49 lung squamous cell carcinoma 10.7 ALK FGFR1 PTPN11 SNHG1 TP53
50 lung papillary adenocarcinoma 10.6 ALK TP53

Graphical network of the top 20 diseases related to Neuroblastoma:



Diseases related to Neuroblastoma

Symptoms & Phenotypes for Neuroblastoma

Human phenotypes related to Neuroblastoma:

60 33 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 neoplasm of the nervous system 60 33 hallmark (90%) Very frequent (99-80%) HP:0004375
2 elevated urinary catecholamines 60 33 hallmark (90%) Very frequent (99-80%) HP:0011976
3 hypertension 33 HP:0000822
4 ataxia 33 HP:0001251
5 failure to thrive 33 HP:0001508
6 fever 33 HP:0001945
7 anemia 33 HP:0001903
8 abdominal pain 33 HP:0002027
9 weight loss 33 HP:0001824
10 abnormality of the thorax 33 HP:0000765
11 myoclonus 33 HP:0001336
12 diarrhea 33 HP:0002014
13 bone pain 33 HP:0002653
14 neuroblastoma 33 HP:0003006
15 ganglioneuroma 33 HP:0003005
16 skin nodule 33 HP:0200036
17 horner syndrome 33 HP:0002277
18 ganglioneuroblastoma 33 HP:0006747
19 opsoclonus 33 HP:0010543
20 spinal cord compression 33 HP:0002176
21 elevated urinary dopamine 33 HP:0011979
22 abdominal mass 33 HP:0031500
23 elevated urinary homovanillic acid 33 HP:0011977
24 elevated urinary vanillylmandelic acid 33 HP:0011978

Symptoms via clinical synopsis from OMIM:

58
Neurologic Central Nervous System:
ataxia
myoclonus
opsoclonus
spinal cord compression
paraneoplastic syndromes

Metabolic Features:
fever

Neoplasia:
ganglioneuroma
ganglioneuroblastoma
neuroblastoma, arises anywhere along the sympathetic chain (including intracranially)
adrenal glands are most common site

Head And Neck Eyes:
horner's syndrome
periorbital ecchymoses (soft tissue involvement)

Chest:
mediastinal mass with calcifications on radiology

Skeletal:
bone pain (with metastatic disease)

Hematology:
anemia (with bone marrow involvement)

Growth Other:
failure to thrive

Abdomen:
abdominal pain
palpable abdominal mass
abdominal mass with calcifications on radiology

Growth Weight:
weight loss (with disseminated disease)

Cardiovascular Vascular:
hypertension (compression of renal arteries)

Abdomen Gastrointestinal:
diarrhea (due to vasoactive intestinal peptide)

Skin Nails Hair Skin:
bluish skin nodules

Laboratory Abnormalities:
increased urinary catecholamines
increased urinary homovanillic acid (hva)
increased urinary vanillylmandelic acid (vma)
increased urinary dopamine
tumor may secrete vasoactive intestinal peptide (vip)

Clinical features from OMIM:

256700

UMLS symptoms related to Neuroblastoma:


seizures, tremor, back pain, pain, headache, syncope, chronic pain, sciatica, vertigo/dizziness, sleeplessness

Drugs & Therapeutics for Neuroblastoma

Drugs for Neuroblastoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 438)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
3
Sargramostim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
4
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 441203 84093 2767
5
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 38904 10339178 498142
6
Itraconazole Approved, Investigational Phase 4,Phase 3,Not Applicable 84625-61-6 55283
7
Panitumumab Approved, Investigational Phase 4,Phase 3 339177-26-3 50070211
8
Docetaxel Approved, Investigational Phase 4,Phase 2,Phase 1 114977-28-5 148124
9
Nicotine Approved Phase 4 54-11-5 942 89594
10 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
11 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Antineoplastic Agents, Immunological Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23
Hydroxyitraconazole Phase 4,Phase 3,Not Applicable
24 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 tyrosine Phase 4,Phase 3,Phase 1,Phase 2
27
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
28
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
29
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
30
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 148-82-3 460612 4053
31
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
32
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
33
Isotretinoin Approved Phase 3,Phase 1,Phase 2,Not Applicable 4759-48-2 5538 5282379
34
Vindesine Approved, Investigational Phase 3,Phase 2,Not Applicable 59917-39-4, 53643-48-4 40839
35
Dacarbazine Approved, Investigational Phase 3,Phase 2,Not Applicable 4342-03-4 5351166
36
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
37
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 123948-87-8, 119413-54-6 60700
38
Aldesleukin Approved Phase 3,Phase 2,Phase 1 85898-30-2, 110942-02-4
39
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 52-24-4 5453
40
rituximab Approved Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
41
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
42
Cobalt Approved, Experimental Phase 3,Phase 2,Phase 1 7440-48-4 104729
43
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 3375-50-6 598
44
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
45
Captopril Approved Phase 3 62571-86-2 44093
46
Palivizumab Approved, Investigational Phase 3 188039-54-5
47
Ribavirin Approved Phase 3 36791-04-5 37542
48
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
49
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
50
Caspofungin Approved Phase 3,Phase 2,Not Applicable 179463-17-3, 162808-62-0 2826718 468682

Interventional clinical trials:

(show top 50) (show all 574)
# Name Status NCT ID Phase Drugs
1 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
2 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
3 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor Recruiting NCT02933333 Phase 4
4 Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC Not yet recruiting NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
5 Combination Chemotherapy Followed By Surgery With or Without Radiation Therapy in Treating Young Patients With Stage II or Stage III Neuroblastoma Unknown status NCT00276731 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
6 Combination Chemotherapy and Surgery With or Without Radiation Therapy in Treating Patients With Stage 2 or Stage 3 Neuroblastoma Unknown status NCT00416676 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;vincristine sulfate
7 Combination Chemotherapy in Treating Infants With Newly Diagnosed Neuroblastoma Who Are Undergoing Surgery With or Without Autologous Bone Marrow or Peripheral Stem Cell Transplant Unknown status NCT00417053 Phase 3 busulfan;carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide phosphate;melphalan;vincristine sulfate
8 Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma Unknown status NCT00030719 Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;isotretinoin;melphalan;vincristine sulfate
9 Observation, Combination Chemotherapy, Radiation Therapy, and/or Autologous Stem Cell Transplant in Treating Young Patients With Neuroblastoma Unknown status NCT00410631 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide phosphate;ifosfamide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate;vindesine
10 123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors Unknown status NCT01373736 Phase 3 123I-meta-iodobenzylguanidine
11 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Unknown status NCT01987596 Phase 3
12 Combination Chemotherapy Followed by Stem Cell Transplant in High-risk Neuroblastoma Patients Completed NCT03042429 Phase 3 Cycles N8, N5 and N6;Cycles N5 and N6
13 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed NCT00499616 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;topotecan hydrochloride;Isotretinoin;Filgrastim
14 Combination Chemotherapy in Treating Young Patients Who Are Undergoing Surgery and an Autologous Bone Marrow Transplant for Disseminated Neuroblastoma Completed NCT00365755 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;melphalan;vincristine sulfate
15 Surgery in Treating Children With Neuroblastoma Completed NCT00003119 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
16 Combination Chemotherapy Before Surgery in Treating Children With Localized Neuroblastoma Completed NCT00025428 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
17 Combination Chemotherapy in Treating Children With Neuroblastoma Completed NCT00003093 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide
18 Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma Completed NCT00002802 Phase 3 carboplatin;cisplatin;cyclophosphamide;dacarbazine;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;mesna;vincristine sulfate;vindesine
19 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma Completed NCT00004188 Phase 3 carboplatin;cisplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;isotretinoin;melphalan;topotecan hydrochloride;vincristine sulfate
20 Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma Completed NCT00126412 Phase 3 123I-mIBG (meta-iodobenzylguanidine)
21 Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma Completed NCT00033293 Phase 3 cyclophosphamide;prednisone;Corticotropin-Releasing Hormone
22 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma Completed NCT01041638 Phase 3 Isotretinoin
23 Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Completed NCT00026312 Phase 3 Isotretinoin
24 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed NCT00567567 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate Liposome
25 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
26 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
27 Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Completed NCT01305200 Phase 3 supersaturated calcium phosphate rinse
28 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
29 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
30 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3 captopril;cyclophosphamide
31 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3 ribavirin
32 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
33 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
34 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
35 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
36 Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer Completed NCT01412957 Phase 3 Panitumumab
37 European Low and Intermediate Risk Neuroblastoma Protocol Recruiting NCT01728155 Phase 3 chemotherapy
38 High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN) Recruiting NCT01704716 Phase 3 Vincristine;Aldesleukin;ch14.18/CHO;Carboplatin;Etoposide;Cisplatin;Cyclophosphamide;Doxorubicin;G-CSF;Busulfan;Melphalan
39 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases Recruiting NCT03275402 Phase 2, Phase 3
40 Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma Recruiting NCT02176967 Phase 3 Carboplatin;Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide
41 Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma Recruiting NCT03126916 Phase 3 Busulfan;Carboplatin;Cisplatin;Crizotinib;Cyclophosphamide;Dexrazoxane Hydrochloride;Doxorubicin Hydrochloride;Etoposide Phosphate;Isotretinoin;Melphalan;Thiotepa;Topotecan Hydrochloride;Vincristine Sulfate
42 Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg) Recruiting NCT01868269 Phase 3 Dexamethasone acetate;dexamethasone and cyclophosphamide;dexamethasone and rituximab
43 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety Recruiting NCT03042416 Phase 3 18F-DOPA
44 Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma Active, not recruiting NCT00554788 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Thiotepa;Vincristine Sulfate
45 Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma Terminated NCT00539500 Phase 2, Phase 3 Carboplatin;Etoposide;Melphalan
46 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
47 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
48 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
49 Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma Unknown status NCT01156350 Phase 2 Busulfan - Fludarabine - TBI
50 Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma Unknown status NCT02615106 Phase 2 Endostar

Search NIH Clinical Center for Neuroblastoma

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: neuroblastoma

Genetic Tests for Neuroblastoma

Genetic tests related to Neuroblastoma:

# Genetic test Affiliating Genes
1 Neuroblastoma 30
2 Neuroblastoma 1 30

Anatomical Context for Neuroblastoma

MalaCards organs/tissues related to Neuroblastoma:

42
Adrenal Gland, Bone, Bone Marrow, Brain, T Cells, Skin, Kidney

Publications for Neuroblastoma

Articles related to Neuroblastoma:

(show top 50) (show all 7350)
# Title Authors Year
1
Novel neuroblastoma amplified sequence (NBAS) mutations in a Japanese boy with fever-triggered recurrent acute liver failure. ( 30622725 )
2019
2
Differences in Genomic Profiles and Outcomes between Thoracic and Adrenal Neuroblastoma. ( 30793172 )
2019
3
Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. ( 30685691 )
2019
4
Crizotinib-induced erosive esophagitis in a pediatric patient with neuroblastoma. ( 29357780 )
2019
5
RNA sequencing reveals a key role for the long non-coding RNA MIAT in regulating neuroblastoma and glioblastoma cell fate. ( 30836187 )
2019
6
5'-Iodotubercidin represses insulinoma associated-1 expression, decreases cAMP levels, and suppresses human neuroblastoma cell growth. ( 30755485 )
2019
7
Transcription of human β4-galactosyltransferase 3 is regulated by differential DNA binding of Sp1/Sp3 in SH-SY5Y human neuroblastoma and A549 human lung cancer cell lines. ( 30561605 )
2019
8
Targeting Anaplastic Lymphoma Kinase in neuroblastoma. ( 30803032 )
2019
9
Novel therapeutic compound acridine-retrotuftsin action on biological forms of melanoma and neuroblastoma. ( 30367436 )
2019
10
Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. ( 30713602 )
2019
11
Multi-functional Nanobio Hybrid Material Composed of Ag@Bi2Se3/RNA Three-Way Junction/miRNA/Retinoic Acid for Neuroblastoma Differentiation. ( 30714374 )
2019
12
Metabolomic Responses to Manganese Dose in SH-SY5Y Human Neuroblastoma Cells. ( 30715528 )
2019
13
miR-34a inhibits progression of neuroblastoma by targeting autophagy-related gene 5. ( 30716314 )
2019
14
TP53 gene rs1042522 allele G decreases neuroblastoma risk: a two-centre case-control study. ( 30719141 )
2019
15
Pelvic neuroblastoma presenting with acute urinary retention and acute kidney injury. ( 30719406 )
2019
16
IRE1α is critical for kaempferol induced neuroblastoma differentiation. ( 30719816 )
2019
17
microRNA-144-3p suppresses human neuroblastoma cell proliferation by targeting HOXA7. ( 30720179 )
2019
18
GDNF family receptor alpha 2 promotes neuroblastoma cell proliferation by interacting with PTEN. ( 30722993 )
2019
19
Inhibition of N-myc expression sensitizes human neuroblastoma IMR-32 cells expressing caspase-8 to TRAIL. ( 30724400 )
2019
20
In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines. ( 30724592 )
2019
21
Adrenocorticotropic Hormone-Dependent Cushing Syndrome Caused by an Olfactory Neuroblastoma. ( 30728732 )
2019
22
Outcomes after Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma. ( 30738983 )
2019
23
Downregulation of PRMT1 promotes the senescence and migration of a non-MYCN amplified neuroblastoma SK-N-SH cells. ( 30741995 )
2019
24
SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro. ( 30744170 )
2019
25
Neuroblastoma of the Iris in Children. ( 30747977 )
2019
26
The Evolution of Risk Classification for Neuroblastoma. ( 30754710 )
2019
27
PRIMA-1MET-induced neuroblastoma cell death is modulated by p53 and mycn through glutathione level. ( 30755224 )
2019
28
Integrative analysis based on survival associated co-expression gene modules for predicting Neuroblastoma patients' survival time. ( 30760313 )
2019
29
Neuroblastoma-A Neural Crest Derived Embryonal Malignancy. ( 30760980 )
2019
30
Technical Note: Simplified and practical pretherapy tumor dosimetry - A feasibility study for 131 I-MIBG therapy of neuroblastoma using 124 I-MIBG PET/CT. ( 30761545 )
2019
31
99mTc-LLEC Renal Dynamic Scan in a Patient With Pelvic Neuroblastoma. ( 30762826 )
2019
32
In vitro evaluation of the protective effects of plant extracts against amyloid-beta peptide-induced toxicity in human neuroblastoma SH-SY5Y cells. ( 30763379 )
2019
33
Reduced-dose Radiation Therapy to the Primary Site is Effective for High-risk Neuroblastoma: Results from a Prospective Trial. ( 30763661 )
2019
34
MYCN-induced E2F5 promotes neuroblastoma cell proliferation through regulating cell cycle progression. ( 30765227 )
2019
35
Correction: Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma. ( 30765869 )
2019
36
Functional high-throughput screening reveals miR-323a-5p and miR-342-5p as new tumor-suppressive microRNA for neuroblastoma. ( 30770954 )
2019
37
Methamphetamine regulates βAPP PROCESSING in human neuroblastoma cells. ( 30771376 )
2019
38
Dual Effect of Doxazosin: Anticancer Activity on SH-SY5Y Neuroblastoma Cells and Neuroprotection on an In Vitro Model of Alzheimer's Disease. ( 30771511 )
2019
39
Neuroblastoma with an unusual ovarian metastasis in a 5-year-old girl. ( 30772831 )
2019
40
GM1 promotes TrkA-mediated neuroblastoma cell differentiation by occupying a plasma membrane domain different from TrkA. ( 30776097 )
2019
41
Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment. ( 30778092 )
2019
42
Real World Experience of Treating Neuroblastoma: Experience from a Tertiary Cancer Centre in India. ( 30778950 )
2019
43
Antitumoral effects of Amblyomma sculptum Berlese saliva in neuroblastoma cell lines involve cytoskeletal deconstruction and cell cycle arrest. ( 30785557 )
2019
44
LncRNAs join hands together to regulate neuroblastoma progression. ( 30788421 )
2019
45
Prussian blue nanoparticle-based antigenicity and adjuvanticity trigger robust antitumor immune responses against neuroblastoma. ( 30789175 )
2019
46
Dissecting Intra-Tumor Heterogeneity by the Analysis of Copy Number Variations in Single Cells: The Neuroblastoma Case Study. ( 30791380 )
2019
47
Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma. ( 30793512 )
2019
48
Catecholamine excretion profiles identify clinical subgroups of neuroblastoma patients. ( 30798085 )
2019
49
Pleiotropic effect of common PHOX2B variants in Hirschsprung disease and neuroblastoma. ( 30799307 )
2019
50
Likelihood of Diagnosing Neuroblastoma in Isolated Horner Syndrome. ( 30801444 )
2019

Variations for Neuroblastoma

ClinVar genetic disease variations for Neuroblastoma:

6 (show top 50) (show all 527)
# Gene Variation Type Significance SNP ID Assembly Location
1 KIF1B NM_015074.3(KIF1B): c.1639+10C> T single nucleotide variant Benign rs3753037 GRCh37 Chromosome 1, 10355834: 10355834
2 KIF1B NM_015074.3(KIF1B): c.1639+10C> T single nucleotide variant Benign rs3753037 GRCh38 Chromosome 1, 10295776: 10295776
3 PHOX2B NM_003924.3(PHOX2B): c.870C> A (p.Pro290=) single nucleotide variant Benign rs17885864 GRCh37 Chromosome 4, 41747899: 41747899
4 PHOX2B NM_003924.3(PHOX2B): c.870C> A (p.Pro290=) single nucleotide variant Benign rs17885864 GRCh38 Chromosome 4, 41745882: 41745882
5 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918453 GRCh37 Chromosome 12, 112888198: 112888198
6 PTPN11 NM_002834.4(PTPN11): c.214G> A (p.Ala72Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121918453 GRCh38 Chromosome 12, 112450394: 112450394
7 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
8 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
9 MSH2 NM_000251.2(MSH2): c.1597C> G (p.Leu533Val) single nucleotide variant Uncertain significance rs786202987 GRCh37 Chromosome 2, 47693883: 47693883
10 MSH2 NM_000251.2(MSH2): c.1597C> G (p.Leu533Val) single nucleotide variant Uncertain significance rs786202987 GRCh38 Chromosome 2, 47466744: 47466744
11 KIF1B NM_015074.3(KIF1B): c.3507G> A (p.Pro1169=) single nucleotide variant Benign/Likely benign rs147318592 GRCh37 Chromosome 1, 10403302: 10403302
12 KIF1B NM_015074.3(KIF1B): c.3507G> A (p.Pro1169=) single nucleotide variant Benign/Likely benign rs147318592 GRCh38 Chromosome 1, 10343244: 10343244
13 KIF1B NM_015074.3(KIF1B): c.2455A> C (p.Ser819Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs140015591 GRCh37 Chromosome 1, 10384871: 10384871
14 KIF1B NM_015074.3(KIF1B): c.2455A> C (p.Ser819Arg) single nucleotide variant Conflicting interpretations of pathogenicity rs140015591 GRCh38 Chromosome 1, 10324813: 10324813
15 KIF1B NM_015074.3(KIF1B): c.2466C> T (p.Asp822=) single nucleotide variant Conflicting interpretations of pathogenicity rs145846362 GRCh37 Chromosome 1, 10384882: 10384882
16 KIF1B NM_015074.3(KIF1B): c.2466C> T (p.Asp822=) single nucleotide variant Conflicting interpretations of pathogenicity rs145846362 GRCh38 Chromosome 1, 10324824: 10324824
17 KIF1B NM_015074.3(KIF1B): c.4458C> T (p.Pro1486=) single nucleotide variant Conflicting interpretations of pathogenicity rs147066476 GRCh38 Chromosome 1, 10365492: 10365492
18 KIF1B NM_015074.3(KIF1B): c.4458C> T (p.Pro1486=) single nucleotide variant Conflicting interpretations of pathogenicity rs147066476 GRCh37 Chromosome 1, 10425550: 10425550
19 ALK NM_004304.4(ALK): c.3833A> C (p.Tyr1278Ser) single nucleotide variant Pathogenic rs863225285 GRCh38 Chromosome 2, 29209789: 29209789
20 ALK NM_004304.4(ALK): c.3833A> C (p.Tyr1278Ser) single nucleotide variant Pathogenic rs863225285 GRCh37 Chromosome 2, 29432655: 29432655
21 ALK NM_004304.4(ALK): c.3734T> G (p.Phe1245Cys) single nucleotide variant Pathogenic rs863225283 GRCh38 Chromosome 2, 29213993: 29213993
22 ALK NM_004304.4(ALK): c.3734T> G (p.Phe1245Cys) single nucleotide variant Pathogenic rs863225283 GRCh37 Chromosome 2, 29436859: 29436859
23 ALK NM_004304.4(ALK): c.3733T> A (p.Phe1245Ile) single nucleotide variant Pathogenic/Likely pathogenic rs281864720 GRCh38 Chromosome 2, 29213994: 29213994
24 ALK NM_004304.4(ALK): c.3733T> A (p.Phe1245Ile) single nucleotide variant Pathogenic/Likely pathogenic rs281864720 GRCh37 Chromosome 2, 29436860: 29436860
25 ALK NM_004304.4(ALK): c.3522C> G (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh38 Chromosome 2, 29220829: 29220829
26 ALK NM_004304.4(ALK): c.3522C> G (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh37 Chromosome 2, 29443695: 29443695
27 ALK NM_004304.4(ALK): c.3522C> A (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh38 Chromosome 2, 29220829: 29220829
28 ALK NM_004304.4(ALK): c.3522C> A (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs863225281 GRCh37 Chromosome 2, 29443695: 29443695
29 ALK NM_004304.4(ALK): c.3520T> C (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs281864719 GRCh38 Chromosome 2, 29220831: 29220831
30 ALK NM_004304.4(ALK): c.3520T> C (p.Phe1174Leu) single nucleotide variant Pathogenic/Likely pathogenic rs281864719 GRCh37 Chromosome 2, 29443697: 29443697
31 ALK NM_004304.4(ALK): c.3520T> A (p.Phe1174Ile) single nucleotide variant Pathogenic rs281864719 GRCh38 Chromosome 2, 29220831: 29220831
32 ALK NM_004304.4(ALK): c.3520T> A (p.Phe1174Ile) single nucleotide variant Pathogenic rs281864719 GRCh37 Chromosome 2, 29443697: 29443697
33 ALK NM_004304.4(ALK): c.3271G> A (p.Asp1091Asn) single nucleotide variant Uncertain significance rs864309584 GRCh37 Chromosome 2, 29446296: 29446296
34 ALK NM_004304.4(ALK): c.3271G> A (p.Asp1091Asn) single nucleotide variant Uncertain significance rs864309584 GRCh38 Chromosome 2, 29223430: 29223430
35 KIF1B NM_015074.3(KIF1B): c.608+8dupA duplication Benign/Likely benign rs139613776 GRCh37 Chromosome 1, 10327624: 10327624
36 KIF1B NM_015074.3(KIF1B): c.608+8dupA duplication Benign/Likely benign rs139613776 GRCh38 Chromosome 1, 10267566: 10267566
37 KIF1B NM_015074.3(KIF1B): c.4882G> A (p.Glu1628Lys) single nucleotide variant Benign/Likely benign rs143669846 GRCh37 Chromosome 1, 10434447: 10434447
38 KIF1B NM_015074.3(KIF1B): c.4882G> A (p.Glu1628Lys) single nucleotide variant Benign/Likely benign rs143669846 GRCh38 Chromosome 1, 10374389: 10374389
39 KIF1B NM_015074.3(KIF1B): c.5112A> G (p.Ala1704=) single nucleotide variant Benign/Likely benign rs75413741 GRCh38 Chromosome 1, 10375007: 10375007
40 KIF1B NM_015074.3(KIF1B): c.5112A> G (p.Ala1704=) single nucleotide variant Benign/Likely benign rs75413741 GRCh37 Chromosome 1, 10435065: 10435065
41 KIF1B NM_015074.3(KIF1B): c.1937A> T (p.Glu646Val) single nucleotide variant risk factor rs121908161 GRCh37 Chromosome 1, 10357264: 10357264
42 KIF1B NM_015074.3(KIF1B): c.1937A> T (p.Glu646Val) single nucleotide variant risk factor rs121908161 GRCh38 Chromosome 1, 10297206: 10297206
43 KIF1B NM_015074.3(KIF1B): c.2480C> T (p.Thr827Ile) single nucleotide variant Likely benign rs121908162 GRCh37 Chromosome 1, 10384896: 10384896
44 KIF1B NM_015074.3(KIF1B): c.2480C> T (p.Thr827Ile) single nucleotide variant Likely benign rs121908162 GRCh38 Chromosome 1, 10324838: 10324838
45 KIF1B NM_015074.3(KIF1B): c.3649C> T (p.Pro1217Ser) single nucleotide variant Likely pathogenic rs121908163 GRCh37 Chromosome 1, 10406001: 10406001
46 KIF1B NM_015074.3(KIF1B): c.3649C> T (p.Pro1217Ser) single nucleotide variant Likely pathogenic rs121908163 GRCh38 Chromosome 1, 10345943: 10345943
47 KIF1B NM_015074.3(KIF1B): c.4442G> A (p.Ser1481Asn) single nucleotide variant Pathogenic,risk factor rs121908164 GRCh37 Chromosome 1, 10425534: 10425534
48 KIF1B NM_015074.3(KIF1B): c.4442G> A (p.Ser1481Asn) single nucleotide variant Pathogenic,risk factor rs121908164 GRCh38 Chromosome 1, 10365476: 10365476
49 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
50 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic rs121918464 GRCh38 Chromosome 12, 112450406: 112450406

Copy number variations for Neuroblastoma from CNVD:

7 (show top 50) (show all 232)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13319 1 1 124300000 Amplification and lo ss Neuroblastoma
2 13325 1 1 124300000 Deletion Neuroblastoma
3 13344 1 1 125000000 Copy number Neuroblastoma
4 13349 1 1 125000000 Deletion Neuroblastoma
5 13355 1 1 125000000 Loss Neuroblastoma
6 13407 1 1 2300000 Copy number GNB1 Neuroblastoma
7 13408 1 1 2300000 Copy number SLC35E2 Neuroblastoma
8 13751 1 1 27800000 Loss Neuroblastoma
9 13762 1 1 28000000 Deletion Neuroblastoma
10 13837 1 10001852 10151200 Loss KIF1B Neuroblastoma
11 16476 1 125000000 249250621 Copy number CHD5 Neuroblastoma
12 16477 1 125000000 249250621 Copy number KIF1B Neuroblastoma
13 16597 1 128000000 247249719 Gain Neuroblastoma
14 16598 1 128000000 247249719 Gain Neuroblastoma
15 17283 1 142400000 148000000 Copy number NBPF23 Neuroblastoma
16 17374 1 142600000 147000000 Copy number NBPF1 Neuroblastoma
17 17375 1 142600000 147000000 Copy number NBPF15 Neuroblastoma
18 17376 1 142600000 147000000 Copy number NBPF3 Neuroblastoma
19 18773 1 147305744 147427061 Copy number NBPF Neuroblastoma
20 20614 1 153300000 247249719 Gain Neuroblastoma
21 20884 1 155000000 249250621 Gain Neuroblastoma
22 26022 1 195715155 196905060 Gain Neuroblastoma
23 27292 1 206429564 209469901 Gain Neuroblastoma
24 29290 1 2300000 12600000 Loss Neuroblastoma
25 29291 1 2300000 12600000 Loss Neuroblastoma
26 29292 1 2300000 12700000 Loss Neuroblastoma
27 32651 1 3815958 4146056 Amplification DFFB Neuroblastoma
28 32934 1 4056522 10472147 Loss Neuroblastoma
29 33588 1 46500000 51300000 Deletion Neuroblastoma
30 34972 1 5871399 5949729 Loss CHD5 Neuroblastoma
31 36107 1 7200000 16200000 Copy number Neuroblastoma
32 37032 1 84700000 88100000 Deletion Neuroblastoma
33 42798 10 40200000 135534747 Loss Neuroblastoma
34 43291 10 46100000 50100000 Gain Neuroblastoma
35 48305 11 1 10700000 Loss Neuroblastoma
36 48306 11 1 10700000 Loss Neuroblastoma
37 48334 11 1 2800000 Gain Neuroblastoma
38 49040 11 102400000 134452384 Deletion Neuroblastoma
39 49300 11 10515175 10701970 Amplification MRVI1 Neuroblastoma
40 49301 11 10515175 10701970 Amplification RNF141 Neuroblastoma
41 49302 11 10515175 10701970 Amplification XLKD1 Neuroblastoma
42 49698 11 110314720 118319416 Loss Neuroblastoma
43 50154 11 114581997 114912893 Loss CADM1 Neuroblastoma
44 51496 11 12700000 16200000 Copy number SOX6 Neuroblastoma
45 52328 11 16100000 21600000 Deletion Neuroblastoma
46 52785 11 19817525 19848438 Amplification NAV2 Neuroblastoma
47 52827 11 2043796 2201921 Amplification IGF2 Neuroblastoma
48 52828 11 2043796 2201921 Amplification INS Neuroblastoma
49 52829 11 2043796 2201921 Amplification TH Neuroblastoma
50 53355 11 2800000 10700000 Duplication LMO1 Neuroblastoma

Expression for Neuroblastoma

LifeMap Discovery
Genes differentially expressed in tissues of Neuroblastoma patients vs. healthy controls: 35 (show top 50) (show all 640)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 STAR steroidogenic acute regulatory protein Adrenal Gland - 9.57 0.000
2 CYP11A1 cytochrome P450, family 11, subfamily A, polypeptide 1 Adrenal Gland - 9.02 0.000
3 CYP11B1 cytochrome P450, family 11, subfamily B, polypeptide 1 Adrenal Gland - 8.90 0.000
4 CYP17A1 cytochrome P450, family 17, subfamily A, polypeptide 1 Adrenal Gland - 8.90 0.000
5 ELAVL4 ELAV like neuron-specific RNA binding protein 4 Adrenal Gland + 8.22 0.000
6 SULT2A1 sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 Adrenal Gland - 8.16 0.000
7 HAND2 heart and neural crest derivatives expressed 2 Adrenal Gland + 8.05 0.000
8 STMN2 stathmin 2 Adrenal Gland + 7.76 0.000
9 PHOX2B paired-like homeobox 2b Adrenal Gland + 7.74 0.000
10 ISL1 ISL LIM homeobox 1 Adrenal Gland + 7.46 0.000
11 CYP21A2 cytochrome P450, family 21, subfamily A, polypeptide 2 Adrenal Gland - 7.45 0.000
12 MGST1 microsomal glutathione S-transferase 1 Adrenal Gland - 7.39 0.000
13 TUBB2B tubulin, beta 2B class IIb Adrenal Gland + 7.37 0.000
14 NPY neuropeptide Y Adrenal Gland + 7.34 0.000
15 GSTA1 glutathione S-transferase alpha 1 Adrenal Gland - 7.21 0.000
16 RTN1 reticulon 1 Adrenal Gland + 7.18 0.000
17 ADGRV1 adhesion G protein-coupled receptor V1 Adrenal Gland - 7.16 0.000
18 SCG2 secretogranin II Adrenal Gland + 7.15 0.000
19 DCX doublecortin Adrenal Gland + 7.06 0.000
20 NRK Nik related kinase Adrenal Gland - 7.01 0.000
21 MAB21L1 mab-21-like 1 (C. elegans) Adrenal Gland + 7.01 0.000
22 MRAP melanocortin 2 receptor accessory protein Adrenal Gland - 7.01 0.000
23 MGARP mitochondria-localized glutamic acid-rich protein Adrenal Gland - 6.97 0.000
24 SLC38A1 solute carrier family 38, member 1 Adrenal Gland + 6.95 0.000
25 RIMBP2 RIMS binding protein 2 Adrenal Gland + 6.84 0.000
26 CD24 CD24 molecule Adrenal Gland + 6.82 0.000
27 GNRHR gonadotropin-releasing hormone receptor Adrenal Gland - 6.80 0.000
28 LDLR low density lipoprotein receptor Adrenal Gland - 6.79 0.000
29 FDX1 ferredoxin 1 Adrenal Gland - 6.79 0.000
30 HMP19 HMP19 protein Adrenal Gland + 6.78 0.000
31 CPB1 carboxypeptidase B1 (tissue) Adrenal Gland - 6.76 0.000
32 CRMP1 collapsin response mediator protein 1 Adrenal Gland + 6.70 0.000
33 SOX11 SRY (sex determining region Y)-box 11 Adrenal Gland + 6.65 0.000
34 SYT1 synaptotagmin I Adrenal Gland + 6.61 0.000
35 GAP43 growth associated protein 43 Adrenal Gland + 6.61 0.000
36 TFAP2B transcription factor AP-2 beta (activating enhancer binding protein 2 beta) Adrenal Gland + 6.59 0.000
37 SCN3A sodium channel, voltage gated, type III alpha subunit Adrenal Gland + 6.57 0.000
38 KRT1 keratin 1, type II Blood - 6.56 0.000
39 CELF4 CUGBP, Elav-like family member 4 Adrenal Gland + 6.53 0.000
40 CHGA chromogranin A Adrenal Gland + 6.45 0.000
41 ELAVL2 ELAV like neuron-specific RNA binding protein 2 Adrenal Gland + 6.41 0.000
42 SCARB1 scavenger receptor class B, member 1 Adrenal Gland - 6.33 0.000
43 IGFBPL1 insulin-like growth factor binding protein-like 1 Adrenal Gland + 6.17 0.000
44 INA internexin neuronal intermediate filament protein, alpha Adrenal Gland + 6.16 0.000
45 SNAP91 synaptosomal-associated protein, 91kDa Adrenal Gland + 6.16 0.000
46 CHRNA3 cholinergic receptor, nicotinic, alpha 3 (neuronal) Adrenal Gland + 6.16 0.000
47 PAK3 p21 protein (Cdc42/Rac)-activated kinase 3 Adrenal Gland + 6.15 0.000
48 STMN4 stathmin-like 4 Adrenal Gland + 6.11 0.000
49 SIGLEC11 sialic acid binding Ig-like lectin 11 Adrenal Gland - 6.05 0.000
50 PDZK1IP1 PDZK1 interacting protein 1 Blood - 6.03 0.000
Search GEO for disease gene expression data for Neuroblastoma.

Pathways for Neuroblastoma

Pathways related to Neuroblastoma according to KEGG:

38
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Neuroblastoma

Sources for Neuroblastoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....